Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...

Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI) Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...